To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Institute for OneWorld Health
The Institute for OneWorld Health is a 501(c)(3) nonprofit pharmaceutical company founded in 2000 to develop safe, effective, and affordable new medicines for people with infectious diseases in the developing countries.
Drug development efforts
Currently, two drugs are under development a drug to treat Chagas disease in Latin America and a drug to cure visceral leishmaniasis in India. Paromomycin, the drug being developed to treat visceral leishmaniasis, was granted orphan drug status in 2005 by both the FDA and EMEA. Prior to this approval, Phase 3 clinical trials for this indication were conducted in India in 2003—2004. The overall conclusion was that efficacy and side effects were similar to the comparison agent in the trials, amphotericin B, results which in August 2006 led to approval for treatment of visceral leishmaniasis by the Indian government.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Institute_for_OneWorld_Health". A list of authors is available in Wikipedia.|